U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C36H35N3O4
Molecular Weight 573.6808
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NDT-9513727

SMILES

CCCCN1C(CN(CC2=CC=C3OCOC3=C2)CC4=CC=C5OCOC5=C4)=C(N=C1C6=CC=CC=C6)C7=CC=CC=C7

InChI

InChIKey=ITACCRHKSPSKKL-UHFFFAOYSA-N
InChI=1S/C36H35N3O4/c1-2-3-18-39-30(35(28-10-6-4-7-11-28)37-36(39)29-12-8-5-9-13-29)23-38(21-26-14-16-31-33(19-26)42-24-40-31)22-27-15-17-32-34(20-27)43-25-41-32/h4-17,19-20H,2-3,18,21-25H2,1H3

HIDE SMILES / InChI

Molecular Formula C36H35N3O4
Molecular Weight 573.6808
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://google.com/patents/WO2002049993A3 | https://www.google.com/patents/WO2003084524A1 | https://google.com/patents/WO2011091366A2

NDT 9513727 is small molecule, orally bioavailable, selective, and potent inverse agonist of the human C5aR. NDT 9513727 inhibited C5a-stimulated responses, including guanosine 5’-3-O-(thio)triphosphate binding, Ca2+ mobilization, oxidative burst, degranulation, cell surface CD11b expression and chemotaxis in various cell types. NDT 9513727 has been shown to effectively inhibit C5a-induced neutropenia in gerbil and cynomolgus macaque in vivo. These results suggest that NDT 9513727 is a promising candidate for the treatment of human inflammatory diseases.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
11.6 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

NDT 9513727 activity was evaluated in C5a-Induced Neutropenia in Cynomolgus Macaque. Two males and two females weighing 3 to 4 kg were used in each experiment, except in the 75 mg/kg study (two males, one female). Animals were given ad libitum access to water during the experiments, but no food was provided during the period of 8 h before to approximately 5 h after drug administration. NDT 9513727 was suspended in 0.5% methylcellulose/0.1% triacetin in water and stirred overnight in the dark before administration. Drug solution or vehicle was administered at doses 5, 25 and 75 mg/kg by nasogastric gavage in a volume of 10 ml/kg body weight.
Route of Administration: Oral
U937 cells were incubated with varying concentrations of NDT 9513727, ranging from 0.1 nM to 4 mkM, for 1 h before the addition of 0.3 nM hC5a (an EC50 concentration). The fluorescence response, upon the subsequent addition of the EC50 concentration of hC5a, was then monitored using an FLIPR.
Substance Class Chemical
Created
by admin
on Sat Dec 16 13:55:52 GMT 2023
Edited
by admin
on Sat Dec 16 13:55:52 GMT 2023
Record UNII
H94WRL71FP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NDT-9513727
Code English
NGD 2000-1
Code English
N,N-BIS(1,3-BENZODIOXOL-5-YLMETHYL)-1-BUTYL-2,4-DIPHENYL-1H-IMIDAZOLE-5-METHANAMINE
Systematic Name English
1H-IMIDAZOLE-5-METHANAMINE, N,N-BIS(1,3-BENZODIOXOL-5-YLMETHYL)-1-BUTYL-2,4-DIPHENYL-
Systematic Name English
Code System Code Type Description
PUBCHEM
10210160
Created by admin on Sat Dec 16 13:55:52 GMT 2023 , Edited by admin on Sat Dec 16 13:55:52 GMT 2023
PRIMARY
CAS
439571-48-9
Created by admin on Sat Dec 16 13:55:52 GMT 2023 , Edited by admin on Sat Dec 16 13:55:52 GMT 2023
PRIMARY
FDA UNII
H94WRL71FP
Created by admin on Sat Dec 16 13:55:52 GMT 2023 , Edited by admin on Sat Dec 16 13:55:52 GMT 2023
PRIMARY
Related Record Type Details
TARGET->INVERSE AGONIST
BINDING
IC50
Related Record Type Details
ACTIVE MOIETY